SNMMI

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

Retrieved on: 
Monday, January 29, 2024
Mortality, Molecular imaging, Booth, Trade, Society, SNMMI, Length of stay, Marketing

Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.

Key Points: 
  • Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.
  • "This conference presents an exciting opportunity to raise awareness and educate SNMMI and ACNM members about the significant impact of our blood volume diagnostic.
  • It underscores their crucial role in providing clinicians with precise information to optimize fluid management treatment, leading to significant reductions in mortality, hospital readmission, length of stay, and costs," said Kathryn Kornafel, Daxor's VP of Marketing and Commercial Development.
  • The Company will be exhibiting at Booth #32.

United Imaging Confirms Installation of Country's First uMI Panorama™ at Huntsman Cancer Institute

Retrieved on: 
Thursday, September 7, 2023
University, SNMMI, NEMA, NCI-designated Cancer Center, Radiology, Huntsman Cancer Institute, National Cancer Institute, Radiation, Patient, PET/CT, FDA, FOV, NCI, Medical imaging, United

HOUSTON, Texas, Sept. 7, 2023 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging (CQCI) at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed another United Imaging PET/CT scanner. This brings state-of-the-art molecular imaging technology to the CQCI clinical research lab. Huntsman Cancer Institute is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI).

Key Points: 
  • HOUSTON, Texas, Sept. 7, 2023 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging (CQCI) at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed another United Imaging PET/CT scanner.
  • Huntsman Cancer Institute is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI).
  • The uMI Panorama was cleared by the FDA in March 2023; Huntsman Cancer Institute is the first to install this groundbreaking technology in the entire United States.
  • In 2022, Huntsman Cancer Institute announced installation of the first United Imaging uMI 780 PET/CT system in North America.

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 14, 2023
GMP, Human, Society, SNMMI, Investment, PSMA, Clinical trial, BCR, SPLASH, ASCO, Development, American Society of Clinical Oncology, Patient, Administration, ACCEL, Annual general meeting, Research, Actinium-225, Pharmaceutical industry, Rare-earth element, Cryptocurrency, M.A

INDIANAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Key Points: 
  • By pairing ligand properties with complementary isotope properties, the potential for therapeutic effect can be efficiently evaluated to optimize clinical development decisions.
  • We continue to anticipate data from the full FRONTIER study to be available in the first half of 2024.
  • Later in June 2023, we published and presented preclinical data at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI).
  • We anticipate a health authority submission in the fourth quarter of 2023, and expect the first patient dosed in this trial to be in the first quarter of 2024.

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Retrieved on: 
Monday, August 14, 2023
Oncology, Cash, Society, State Administrative Expenses, SNMMI, Multiple myeloma, Molecular imaging, NDA, Cancer, G&A, Research, CNSL, Development, Patient, Hand, Conference, Fine chemical, Pharmaceutical industry, Medical imaging, Cryptocurrency

FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • The company plans to initiate its Phase 1b study in pediatric high-grade gliomas (pHGG) in the third quarter of 2023.
  • The central nervous system lymphoma (CNSL) cohort from its Phase 2a trial expanded to further evaluate iopofosine I 131 in this indication.
  • The company believes its cash on hand is adequate to fund budgeted operations into the fourth quarter of 2023.

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023
GMP, Mayo Clinic, GE HealthCare, Safety, Glomus tumor, Doctor of Philosophy, Audit committee, Medicare, Journal, CATX, Patient, Investment, RLS, R, ED, NYSE, Brain, Prostate cancer, Centers for Medicare & Medicaid Services, University, Viewpoint, Fortis Healthcare, Research, Nuclear medicine, Rated R, Radiosurgery, Radiation, Knowledge, Growth, FDA, Bander, SPECT, GT, Roche, Isotopes of thorium, USP, 1991 World Sportscar Championship, Documentation, International Symposium on Endovascular Therapy, Neurosurgery, Therapy, Joint Commission, Isotopes of caesium, SNMMI, MC1R, Molecular imaging, PET, University of Iowa, CDMO, Melanoma, Medical imaging, Pharmaceutical industry, Management, Health insurance, MD, Brachytherapy, Operation

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

Key Points: 
  • RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.
  • With a strong team in place, we’re focused on securing new business and re-gaining old business.
  • For the first half of fiscal 2023 ended June 30, 2023, revenue decreased 23% to $4.2 million versus $5.4 million in the prior year comparable period.
  • Prostate brachytherapy represented 42% of total revenue for the first six months of fiscal 2023 compared to 73% for the first six months of fiscal 2022.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Retrieved on: 
Friday, August 11, 2023
Yale University, Society, Mayo Clinic, University, SNMMI, Maxima and minima, MC1R, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, University of Wisconsin–Madison, University of Iowa, Index, MFD, Washington University in St. Louis, Immunotherapy, Perspective, Trial of the century, CDMO, CATX, Patient, Melanoma, MTD, Toxic leukoencephalopathy, Principal, Therapy, Saint Louis University, Jan Vansina, NYSE, SPECT, Safety, Medical imaging

The trial is a first-in-human, non-randomized, multi-center open-label dose escalation, dose expansion study of 212Pb-VMT01 in patients with histologically confirmed melanoma and a positive MC1R imaging scan.

Key Points: 
  • The trial is a first-in-human, non-randomized, multi-center open-label dose escalation, dose expansion study of 212Pb-VMT01 in patients with histologically confirmed melanoma and a positive MC1R imaging scan.
  • “MC1R is implicated in the development of melanoma making it a promising target for potential treatment using radionuclide therapy,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “Today we achieved an important milestone as we work to access the potential of VMT01 as a targeted alpha-particle therapy for MC1R+ metastatic melanoma."
  • Additional CDMO manufacturing sites are expected to be brought online in the coming months to enable broader coverage for sites across the US.

United Imaging, Kicking off a Birthday Celebration of Five Years in the U.S. Market, Will Debut Three New Scanners at AHRA

Retrieved on: 
Wednesday, July 5, 2023
Acceleration, Federal Food, Drug, and Cosmetic Act, CT, SNMMI, Senior, Noise, UVision Air, Workflow, Curriculum, Life, Intelligence, MRI, Umi, Software Upgrade Protocol, Radiation, Patient, AI, Environment, AHRA, ATLAS, Medical imaging

HOUSTON, Texas, July 5, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, continued its acceleration in investment and innovation for the U.S. market by announcing plans to officially show three new commercially available products (in MRI, DR, and CT), in Indianapolis at the AHRA Annual Meeting.

Key Points: 
  • United Imaging today manufactures scanners in four imaging modalities for the United States.
  • We've just not experienced that because of the way we are so vertically integrated throughout Houston and our other factories."
  • And third, we invest heavily in reducing the noise and increasing homogeneity in the system versus simply increasing signal.
  • That allows higher imaging quality in reduced time slots, to increase exams without expanding staffing or hours of operation."